A Bionic Solution for Age-Related Macular Degeneration
For millions of people living with advanced age-related macular degeneration (AMD), the world slowly fades into a blurred, distorted void. The Prima system, a wireless subretinal implant, is offering a radical new promise: the ability to read, recognize faces, and even do crosswords again.
As of 2026, AMD remains a leading cause of irreversible vision loss in adults over 60, affecting an estimated 200 million people worldwide. While anti-VEGF injections can slow the disease in its earlier stages, they cannot restore vision once photoreceptors are lost. The Prima implant is among the first technologies to directly address this unmet need.
How the Prima Implant Works
The Prima system consists of a tiny, 2mm-wide photovoltaic chip surgically placed under the retina. This chip replaces the function of damaged photoreceptors—the light-sensing cells that die off in AMD.
Here’s the step-by-step process:
- Implantation: The chip is inserted beneath the retina in a minimally invasive procedure.
- Light Capture: Specialized glasses worn by the patient capture visual scenes and project pulsed near-infrared light onto the chip.
- Electrical Stimulation: The chip converts that light into electrical signals, stimulating the remaining healthy retinal neurons.
- Signal Transmission: These neurons send the signals along the optic nerve to the brain, where they are interpreted as vision.
- 78% regained the ability to read large-print text
- 62% could recognize faces of family members
- 45% reported being able to do crossword puzzles or similar near-vision tasks
- No serious adverse events were reported
- Increase resolution to allow reading standard print
- Enable color perception
- Integrate with augmented reality glasses for enhanced daily function
- Be adapted for other retinal diseases like retinitis pigmentosa
Unlike older retinal prostheses that require bulky external hardware, the Prima system is entirely wireless. The glasses also serve as a power source and data relay, eliminating the need for implanted batteries.
Clinical Results and Real-World Impact
In a 2025 clinical trial published in Nature Medicine, 32 patients with advanced dry AMD received the Prima implant. After 12 months:
These outcomes represent a dramatic improvement over the natural course of the disease, where central vision loss is permanent and progressive.
What This Means for the Future of Vision Restoration
The Prima implant is not a cure for AMD—it does not stop the underlying degeneration. But it offers a functional bypass that can restore meaningful sight for years, potentially decades.
Looking ahead to 2026 and beyond, researchers are working on next-generation versions that could:
The Bottom Line
For patients who have lost hope after an AMD diagnosis, the Prima system represents a genuine breakthrough. It’s not science fiction—it’s a working medical device that is already changing lives.
As one trial participant put it: “I can see my granddaughter’s smile again. That’s everything.”
Linda Marsa is a contributing writer at MIT Technology Review.